Zhihong Wang Tianmei Zeng Yong Li Ding Zhang Zhengang Yuan Mengli Huang Yuan Yang Weiping Zhou
10.3389/fimmu.2021.799822
Front Immunol
2021 Dec 24;12:799822.
biomarker (bm) capecitabine immunotherapy intrahepatic cholangiocarcinoma (icca) maintenance therapy
CC BY
https://pubmed.ncbi.nlm.nih.gov/35003124/
Antibodies, Monoclonal, Humanized / administration & dosage Bile Duct Neoplasms / drug therapy Capecitabine / administration & dosage Cholangiocarcinoma / drug therapy Immune Checkpoint Inhibitors / administration & dosage Maintenance Chemotherapy / methods
Antibodies, Monoclonal, Humanized / administration & dosage Bile Duct Neoplasms / drug therapy Capecitabine / administration & dosage Cholangiocarcinoma / drug therapy Immune Checkpoint Inhibitors / administration & dosage Maintenance Chemotherapy / methods Case Reports Research Support, Non-U.S. Gov't Review Antineoplastic Combined Chemotherapy Protocols / therapeutic use Humans Male Middle Aged Antibodies, Monoclonal, Humanized Immune Checkpoint Inhibitors Capecitabine sintilimab
PMC8739978
35003124
PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
2021